Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection
Sorrento Therapeutics, Inc. (SRNE)
Last sorrento therapeutics, inc. earnings: 8/9 04:49 pm
Check Earnings Report
US:NASDAQ Investor Relations:
sorrentotherapeutics.com/investors
Company Research
Source: GlobeNewswire
SAN DIEGO and WARREN, N.J., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has initated a clinical and manufacturing collaboration with Celularity, Inc., a Warren, New Jersey, based clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies derived from the postpartum human placenta. The objective of the collaboration is to expand the therapeutic use of Celularity's CYNK-001, an allogeneic, off-the-shelf, placental-derived Natural Killer (NK) cell therapy, to the treatment and prevention of coronavirus infections. NK cells are the foundation of the natural innate immune response. NK cells derived from the placenta are well tolerated, intrinsically safe and versatile, allowing potential uses across a range of organs and tissues. NK cell therapy is currently being investigated as a treatment for various liquid and solid tumors, but also has the demonstrated potential to be effective against v
Show less
Read more
Impact Snapshot
Event Time:
SRNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRNE alerts
High impacting Sorrento Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRNE
News
- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat